Participated · Series C · Jun 2026

NewLimit develops age-reprogramming medicines by using an AI-driven genomics platform to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated that program toward clinical development. NewLimit plans to transition its lead liver-cell program into investigator-led human trials targeted for late 2027 and to expand its computational biology teams to support pipeline growth. Financially, the company raised $435 million in a Series C led by Founders Fund with broad participation from venture firms and strategic investors. NewLimit was co-founded by Brian Armstrong and Blake Byers and is led by CEO and President Jacob Kimmel.

Participated · Series D · Feb 2024

BioAge develops novel therapies for obesity and metabolic diseases by leveraging human aging biology and a discovery platform built on human longevity data. Its lead program, azelaprag, is an oral apelin receptor (APJ) agonist described as a potential first-in-class agent entering Phase 2 trials in combination with tirzepatide. In Phase 1b, azelaprag promoted muscle metabolism, increased energy expenditure, and prevented muscle atrophy in healthy older volunteers at bedrest; preclinical studies showed it doubled weight loss achieved on incretin drugs with improved body composition and muscle function. The company plans Phase 2 studies of azelaprag in combination with Lilly’s Zepbound (tirzepatide) and other incretins, with Zepbound studies expected to begin mid-2024 in collaboration with Eli Lilly’s Chorus. BioAge also maintains earlier-stage preclinical programs addressing pathways in metabolic aging. The announced financing will support these clinical programs and key upcoming data readouts.

Participated · Series D · Feb 2024

BioAge Labs uses insights from human aging to discover targets and develop therapies for metabolic diseases. Its lead program, azelaprag, is an oral APJ (apelin) receptor agonist being advanced as a potential first-in-class oral regimen to amplify weight loss and improve body composition when combined with incretin drugs. In a Phase 1b trial azelaprag promoted muscle metabolism, increased energy expenditure, and prevented muscle atrophy in healthy older volunteers; preclinical studies showed it doubled weight loss achieved with incretins and improved body composition and muscle function. The company plans Phase 2 combination studies of azelaprag with Lilly’s Zepbound (tirzepatide), expected to begin in mid-2024 in collaboration with Eli Lilly’s Chorus. BioAge also continues to advance earlier-stage metabolic aging programs derived from its discovery platform built on human longevity data. The company completed an oversubscribed $170 million Series D to fund these clinical programs and pipeline advancement. BioAge Labs develops proprietary drugs aimed at treating aging and age-related diseases by using datasets and an AI-driven platform to identify molecular drivers of age-related pathology. The company is advancing a pipeline of therapies that target key pathways to increase healthspan and lifespan. Proceeds from its recent financing will be used to build a diversified portfolio of therapies and to augment its AI capabilities. BioAge also plans to expand its capabilities to test drug candidates in predictive models of human diseases of aging. Led by co-founder and CEO Kristen Fortney, the company emphasizes translating molecular insights into candidate therapies. The company announced the appointment of Paul Rubin, M.D., as chief medical officer to lead clinical development efforts. BioAge Labs is a Berkeley, CA-based developer of a machine-learning powered platform that measures human aging and accelerates drug discovery. The company's platform focuses on identifying and refining signatures of aging to target diseases where aging is causal. Leadership includes CEO Kristen Fortney, PhD; Chris Morrissey, PhD, Head of Bioinformatics; and Jonah Sinick, PhD, Head of Data Science. BioAge raised $10.9M in a Series A financing to support its development and early-stage work. It plans to use the funds to build its team, refine and test its aging signatures, and begin in vivo evaluation of drug candidates. Ultimately the company aims to combat suffering and disability from aging-related diseases and to restore both quality and quantity of life in old age.

Participated · Series E · Jul 2018

Sutro Biopharma is a clinical-stage drug discovery, development and manufacturing company creating next-generation protein therapeutics for oncology and autoimmune disorders using proprietary integrated cell-free protein synthesis and site-specific conjugation platforms, XpressCF™ and XpressCF+™. Its pipeline includes cytokine-based immuno-oncology therapeutics, antibody drug conjugates (ADCs), and bispecific antibodies directed mainly at clinically validated targets. The company has two internally developed ADCs highlighted in the articles: STRO-001, in Phase 1 testing for lymphoma and multiple myeloma, and STRO-002, expected to enter clinical trials for ovarian and endometrial cancer by early 2019. Sutro also collaborates with select pharmaceutical and biotech companies to discover and develop novel therapeutics. The company plans to use recent financing to advance its oncology pipeline, further early-stage programs, and continue platform technology advancement. Sutro is led by CEO Bill Newell and is based in South San Francisco, CA. Sutro Biopharma develops new protein therapeutics using its cell-free protein synthesis technology to create antibody drug conjugates and bispecific antibodies. The company has established a cGMP facility for production of clinical supplies. It has formed partnerships with biopharma companies, including a collaboration with Celgene to design and develop novel ADCs and bispecific antibodies and to manufacture a proprietary Celgene antibody. Led by CEO William J. Newell, Sutro intends to use the funds to expand its proprietary immuno-oncology product pipeline. Founded in 2003 and based in South San Francisco, the company has raised over $90M since its founding. It secured a $26M Series D to support pipeline and manufacturing expansion. Sutro Biopharma is a San Francisco-based company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. The company has developed biochemical synthesis technology that allows rapid and systematic exploration of many protein drug variants to identify drug candidates. Sutro develops its own drug pipeline and collaborates with select pharmaceutical and biotech companies in the discovery and development of novel protein therapeutics. Led by CEO William Newell, the company closed a $16.5M second tranche of its Series C financing. The financing was announced on 09/05/2012. Sutro Biopharma develops and designs novel protein therapeutics and biosuperiors with site-directed modifications, including incorporation of non-natural amino acids. The company operates a biochemical protein synthesis platform used to create site-directed modified proteins. Sutro intends to use the new capital to further advance its biotherapeutics and to bring its protein synthesis platform to current Good Manufacturing Practice (cGMP) standards. It secured $36.5m in a Series C financing that consists of two tranches, with the first $20m tranche closed on Nov. 5. To date the company has raised a total of $59.5m in financing. In conjunction with the financing Dr. Chen and Armen Shanafelt, Ph.D. joined Sutro’s board of directors.

Participated · Equity · Jun 2018

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company that designs and develops novel small molecule medicines using its computational drug discovery engine and machine-learning–based predictive modeling. Its pipeline includes the clinical-stage HPK1 inhibitor NDI-101150 for solid tumors and a diverse portfolio of preclinical programs focused on cancer, autoimmune conditions and metabolic diseases, including WRN and an undisclosed autoimmune target. Nimbus is advancing novel targeted therapies that activate AMPK through a collaboration with Eli Lilly. The company will use proceeds from its recent financing to advance multiple preclinical programs into and through early clinical development and to continue clinical development of NDI-101150. Nimbus emphasizes integrating computational chemistry with high-tech structural biology tools to tackle difficult-to-drug targets. The company is headquartered in Boston, MA. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company that combines computational technologies and machine learning to design novel small-molecule medicines. The company focuses on programs across inflammatory and autoimmune disorders, cancer, and metabolic diseases and has three internally discovered compounds that have advanced into clinical trials. Lead clinical programs include NDI-034858, an oral allosteric TYK2 inhibitor in Phase 2b for plaque psoriasis and psoriatic arthritis (with planned Phase 3 initiation), and NDI-101150, an HPK1 inhibitor in Phase 1/2 for solid tumors. Nimbus is also advancing preclinical programs targeting Cbl-b and WRN and continues discovery efforts across multiple targets. The recent financing is intended to fund completion and initiation of multiple clinical trials and ongoing preclinical and discovery work. Nimbus is headquartered in Cambridge, MA. Nimbus Therapeutics designs potent, selective small-molecule compounds using a structure-based drug discovery engine to target proteins that drive pathology in prevalent diseases. The company’s LLC/subsidiary architecture enables diverse partnerships to advance programs. Its pipeline includes a novel allosteric TYK2 inhibitor with compelling data and an HPK1 inhibitor candidate slated for first-in-human studies in solid tumors. Nimbus plans multiple Phase 2 clinical studies of the TYK2 inhibitor in 2021 and 2022 and expects to begin IND-enabling studies on two novel agents in 2022. The financing will also accelerate preclinical programs across oncology and immunology. Nimbus is headquartered in Cambridge, Mass. Nimbus Therapeutics is a Cambridge, Mass.-headquartered biotechnology company that designs small-molecule medicines using a structure-based drug discovery engine. Its approach focuses on potent and selective small-molecule compounds targeting proteins that drive pathology in prevalent diseases, and the company uses an LLC/subsidiary architecture to enable diverse partnerships. Nimbus announced a $60 million private financing from RA Capital Management and BVF Partners to accelerate its pipeline. The funds will support advancing its Phase 1 allosteric TYK2 inhibitor into Phase 2 early next year, moving its HPK1 inhibitor into the clinic next year, and advancing its preclinical portfolio. RA Capital's Laura Stoppel will join the Nimbus board as part of the financing. Company leadership said the financing defines a pathway for future investment and that they expect to bring on additional new investment in 2021 with continued success. Nimbus Therapeutics applies deep computational expertise across drug discovery and development to design novel treatments for metabolic disease, cancer and immune‑inflammatory disorders. The company combines massive computational‑chemistry capabilities with founding partner Schrödinger and leverages structural biology, cryo‑EM, and machine‑learning–augmented ADMET prediction. Its current portfolio includes Tyk2 inhibitors and STING antagonists partnered under an immunology alliance with Celgene, and a wholly owned STING agonist program with compelling preclinical small‑molecule data. Nimbus plans to expand discovery into new high‑value targets that overlap biological mechanisms in immunology, oncology, and metabolic disease, and to advance several undisclosed target programs toward the clinic in the next few years. The company announced $65 million in new capital to accelerate pipeline progress and expand discovery efforts. Proceeds from this financing together with business‑development activity have helped Nimbus remain a privately held LLC and build a nine‑figure balance sheet to support rapid advancement and partnerships. The company is headquartered in Cambridge, Massachusetts.